Genentech Paid $100 Million for Alector’s Parkinson Enzyme but Not Its Brain Shuttle
Alector said on 5 October it has granted Genentech, a member of the Roche Group, exclusive worldwide rights to AL050, an engineered glucocerebrosidase (GCase) enzyme replacement therapy for Parkinson’s disease, in exchange for an upfront payment, milestones and tiered royalties. AL050 pairs an enzyme optimised for activity and half-life with the Alector Brain Carrier, a platform designed to move therapeutics across the blood-brain barrier, to clear the lipids that build up when GCase is deficient, most markedly in carriers of GBA1 mutations. The programme has not yet entered the clinic. Genentech takes over development, manufacturing and commercialisation, while Alector keeps ownership of the brain carrier and the right to use it across its own pipeline.
Genentech licensed the enzyme and left the shuttle with Alector. Roche already runs its own blood-brain barrier shuttle in trontinemab, so this deal buys a Parkinson’s asset rather than a delivery platform. Alector keeps the carrier under its remaining pipeline, and now has the cash to use it.
- GBA1 Parkinson’s developers: enzyme replacement now has a big-pharma sponsor. Other GCase approaches include small-molecule activators and gene therapy; AL050 delivers the enzyme itself into the brain. Genentech takes on the class before any human data exist, which raises the bar for rivals seeking a partner on preclinical packages.
- Blood-brain barrier platform owners: the inventor kept the engine. Alector licensed one payload and retained the carrier, the structure a platform company uses to monetise assets without selling its core technology. Other shuttle owners will now price their own preclinical deals against this one.
- Signposts: the first patient and the 13 October webinar. AL050’s first-in-human start under Genentech is the next marker. Alector says the deal extends its cash runway into 2029, and on 13 October it presents its anti-amyloid antibody AL137 and its tau and alpha-synuclein siRNA programmes, which will show what the platform does in its own hands.